| Time interval | ART eligibility criteria | |||
| <200 CD4 cells ×106/l | <275 CD4 cells ×106/l | <350 CD4 cells ×106/l | <350 CD4 cells ×106/l and WHO stage 3 | |
| All cohorts | ||||
| Seroconversion to eligibility (years) | ||||
| Median (95% CrI) | 6.1 (3.3–10.4) | 4.2 (1.9–7.9) | 2.7 (0.9–6.3) | 5.6 (5.0–6.2) |
| Mean (95% CrI) | 7.6 (4.1–12.9) | 5.4 (2.5–10.3) | 4.0 (1.4–9.2) | 6.4 (5.8–7.1) |
| Percentage* | 66 (38–87) | 48 (23–75) | 34 (12–64) | 58 (50–65) |
| Eligibility to death (years) | ||||
| Median (95% CrI) | 2.1 (0.7–4.8) | 4.0 (1.7–8.0) | 6.0 (2.9–11.7) | 3.0 (2.4–3.8) |
| Mean (95% CrI) | 3.9 (1.4–9.1) | 5.9 (2.5–11.7) | 7.7 (3.8–15.0) | 4.5 (3.5–6.4) |
| Percentage* | 34 (13–62) | 52 (25–78) | 66 (36–88) | 42 (35–50) |
| Excluding the two Thai cohorts | ||||
| Seroconversion to eligibility (years) | ||||
| Median (95% CrI) | 7.6 (3.4–15.2) | 4.8 (1.9–11.6) | 3.2 (1.0–9.7) | 5.6 (5.1–6.2) |
| Mean (95% CrI) | 9.4 (4.3–19.2) | 6.3 (2.4–15.1) | 4.8 (1.5–14.4) | 6.4 (5.8–7.1) |
| Eligibility to death (years) | ||||
| Median (95% CrI) | 2.7 (0.8–8.4) | 5.0 (1.6–13.8) | 7.6 (3.0–18.3) | 3.0 (2.4–3.8) |
| Mean (95% CrI) | 5.2 (1.5–15.9) | 7.4 (2.5–20.5) | 9.8 (3.8–23.7) | 4.5 (3.5–6.4) |
*Percentage of duration from seroconversion to death.
CrI, credibility interval.